ArticlePLOS digital health2026
Automated identification of keratinocyte cancers in pathology reports using large language models.
Article in PLOS digital health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Keratinocyte cancers (KCs) are the most prevalent cancers in white-skinned individuals, yet remain underrepresented in cancer registries because reporting requirements differ greatly across jurisdictions. Manual extraction of KC subtypes from medical reports is labor-intensive and time-consuming, particularly as reports often document multiple co-excised skin lesions. Artificial intelligence offers automated solutions for disease phenotyping from unstructured clinical text. We fine-tuned the open-source large language model Meta-AI (LLaMA) 3.1-8B-Instruct on 26,179 manually reviewed pathology reports from 10,326 Australian QSkin Sun and health study participants who had histologically confirmed KCs. Independently validation was performed on 217 pathology reports from the Skin Tumors in Allograft Recipients cohort. The model achieved F1-scores above 0.90 for the four KC subtypes of interest: squamous cell carcinoma, basal cell carcinoma, keratoacanthoma, and intraepidermal carcinoma. Frequency-weighted mean F1-scores reached 0.84 (95% confidence interval: 0.843-0.846) for diagnosis classification and 0.83 (95% confidence interval: 0.826-0.828) for anatomical site. External validation demonstrated robust performance with F1-scores between 0.73-0.86 for the four KCs of interest. Our fine-tuned model QSkin-llama-3.1-8b works locally. It accurately classifies lesion counts, diagnoses, and anatomical sites. It processes 24 pathology reports per minute with minimal preprocessing, enabling scalable automated disease phenotyping for large health datasets.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.